Coffee Consumption and All-Cause, Cardiovascular, and Cancer Mortality in an Adult Mediterranean Population.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
09 Apr 2021
Historique:
received: 17 03 2021
revised: 04 04 2021
accepted: 07 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 28 5 2021
Statut: epublish

Résumé

We assessed the association between usual coffee consumption and all-cause, cardiovascular (CV), and cancer mortality in an adult population in Spain, taking into account both the amount and type of coffee consumed. We used baseline data on coffee consumption and other personal variables, and the number of deaths during an 18-year follow-up period, for 1567 participants aged 20 years and older from the Valencia Nutrition Study in Spain. Total, caffeinated, and decaffeinated coffee consumption was assessed using a validated food frequency questionnaire. Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). During the 18-year follow-up period, 317 died; 115 due to CV disease and 82 due to cancer. Compared with no-consumption, the consumption of ≤1 cup per day and >1 cup per day of coffee was associated with a lower risk of all-cause mortality, HR = 0.73 (95% CI: 0.56-0.97) and HR 0.56 (95% CI: 0.41-0.77), respectively. A lower cancer mortality was observed among drinkers of more than 1 cup per day compared with nondrinkers, HR 0.41 (95% CI 0.20-0.86). Regarding the type of coffee, only the overall consumption of caffeinated coffee was associated with lower all-cause mortality at 12 and 18 years of follow-up, HR = 0.66 (95% CI:0.46-0.94) and HR = 0.59 (95% CI: 0.44-0.79), respectively. In conclusion, this study suggests that the moderate consumption of coffee, particularly caffeinated coffee (range 1-6.5 cups per day), is associated with a lower all-cause and cancer mortality after a long follow-up period. No significant association was found between coffee consumption and CVD mortality.

Identifiants

pubmed: 33918797
pii: nu13041241
doi: 10.3390/nu13041241
pmc: PMC8070495
pii:
doi:

Substances chimiques

Coffee 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The VNS study was supported by a grant from the Dirección General de Salud Pública, Generalitat Valenciana 1994 and the Fondo Investigacion Sanitaria
ID : (FIS 00/0985)
Organisme : This study has also received support from the Instituto de Salud Carlos III and FEDER funds
ID : (FIS PI13/00654)

Références

Crit Rev Food Sci Nutr. 2019;59(2):336-348
pubmed: 28853910
N Engl J Med. 2003 Jun 26;348(26):2599-608
pubmed: 12826634
Am J Epidemiol. 2009 Dec 15;170(12):1518-29
pubmed: 19903723
Cancer Sci. 2017 Oct;108(10):2079-2087
pubmed: 28746796
Nutrition. 2016 Jun;32(6):628-36
pubmed: 26944757
Am J Epidemiol. 2017 Jun 15;185(12):1304-1316
pubmed: 28472215
BMJ. 2017 Nov 22;359:j5024
pubmed: 29167102
Am J Epidemiol. 2014 Oct 15;180(8):763-75
pubmed: 25156996
Annu Rev Nutr. 2017 Aug 21;37:131-156
pubmed: 28826374
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Crit Rev Food Sci Nutr. 2006;46(2):101-23
pubmed: 16507475
Eur J Epidemiol. 2016 Dec;31(12):1191-1205
pubmed: 27699514
Eur J Epidemiol. 2019 Aug;34(8):731-752
pubmed: 31055709
Am J Clin Nutr. 2018 Nov 1;108(5):1113-1120
pubmed: 30475964
BMJ. 1995 Dec 2;311(7018):1457-60
pubmed: 8520331
Ann Intern Med. 2017 Aug 15;167(4):228-235
pubmed: 28693036
Br J Nutr. 2008 Jun;99(6):1354-61
pubmed: 18062826
Eur J Nutr. 2016 Jun;55(4):1345-58
pubmed: 27026242
Circ J. 2019 Mar 25;83(4):757-766
pubmed: 30853684
J Nutr. 2021 Feb 1;151(2):395-404
pubmed: 33382422
Eur J Clin Nutr. 2018 Jan;72(1):30-43
pubmed: 28488692
Am J Public Health. 1989 Nov;79(11):1554-6
pubmed: 2817172
Food Funct. 2014 Aug;5(8):1695-717
pubmed: 24671262
Trends Endocrinol Metab. 2014 Oct;25(10):489-92
pubmed: 25124982
Int J Cardiol. 2016 Jun 1;212:131-7
pubmed: 27038718
Am J Epidemiol. 1989 Feb;129(2):233-48
pubmed: 2643301
Eur J Epidemiol. 2013 Jul;28(7):527-39
pubmed: 23934579
Med Clin (Barc). 1998 Mar 7;110(8):319
pubmed: 9567263
Ann Intern Med. 2017 Aug 15;167(4):236-247
pubmed: 28693038
Mayo Clin Proc. 2013 Oct;88(10):1066-74
pubmed: 23953850
Appetite. 2012 Jun;58(3):971-7
pubmed: 22326679
Eur J Nutr. 2017 Feb;56(1):1-12
pubmed: 27388462
Eur J Clin Nutr. 2012 Aug;66(8):872-7
pubmed: 22713771
Clin Nutr. 2017 Jun;36(3):730-736
pubmed: 27288328
Public Health Nutr. 2017 Jan;20(1):82-91
pubmed: 27411779
Eur J Cancer Prev. 2017 Sep;26(5):368-377
pubmed: 27111112
BMC Cancer. 2011 Mar 15;11:96
pubmed: 21406107
Circulation. 2015 Dec 15;132(24):2305-15
pubmed: 26572796
BMJ. 1995 Jul 15;311(6998):158-61
pubmed: 7613427
Eur J Nutr. 2019 Jun;58(4):1415-1427
pubmed: 29549497
Br J Nutr. 2014 Apr 14;111(7):1162-73
pubmed: 24279995
Antioxidants (Basel). 2018 Feb 04;7(2):
pubmed: 29401716
Diabetes Care. 2014 Feb;37(2):569-86
pubmed: 24459154
Eur J Nutr. 2019 Sep;58(6):2439-2448
pubmed: 30066178

Auteurs

Laura Torres-Collado (L)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Laura María Compañ-Gabucio (LM)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Sandra González-Palacios (S)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Leyre Notario-Barandiaran (L)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Alejandro Oncina-Cánovas (A)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Jesús Vioque (J)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Manuela García-de la Hera (M)

Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 03010 Alicante, Spain.
Unidad de Epidemiología de la Nutrición, Departamento de Salud Pública, Historia de la Ciencia y Ginecología, Universidad Miguel Hernández (UMH), 03550 Alicante, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28034 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH